Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 2/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | TLR2 | O60603 | 1/20 | 0.37 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14428332 | 0.90 | KMT2A (0.44) | BACE1KMT2AL3MBTL1HSD11B1CASP1 | |
| SCHEMBL1913212 | 0.86 | KMT2A (0.43) | KCNA3BACE1KMT2AL3MBTL1CASP1 | |
| SCHEMBL1913192 | 0.86 | KMT2A (0.43) | KCNA3BACE1KMT2AL3MBTL1CASP1 | |
| SCHEMBL1913190 | 0.86 | KMT2A (0.43) | KCNA3BACE1KMT2AL3MBTL1CASP1 | |
| SCHEMBL1913332 | 0.86 | KMT2A (0.43) | KCNA3BACE1KMT2AL3MBTL1CASP1 | |
| SCHEMBL8249851 | 0.85 | KMT2A (0.40) | BACE1KMT2AL3MBTL1HSD11B1CASP1 | |
| SCHEMBL19180879 | 0.85 | KMT2A (0.40) | BACE1KMT2AL3MBTL1HSD11B1CASP1 | |
| SCHEMBL17101876 | 0.84 | KCNA3 (0.44) | KCNA3KMT2AL3MBTL1CTSKKDM1A | |
| SCHEMBL17101875 | 0.83 | KMT2A (0.41) | KCNA3BACE1KMT2AL3MBTL1HSD11B1 | |
| SCHEMBL3489490 | 0.82 | HSD11B1 (0.50) | KCNA3HSD11B1CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771360-B2 | Cyano-substituted imidazo[1,2-A]pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-26 | — | — | US | disclosed |
| US-20170217954-A1 | CYANO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-03 | — | — | US | disclosed |
| EP-3119777-A1 | CYANO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE | Bayer Pharma Aktiengesellschaft (DE) | 2017-01-25 | — | — | EP | disclosed |
| WO-2015140199-A1 | CYANO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217954-A1 | CYANO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE | AADAC, TNNI3, PCCA | KCNA3 938/4885BACE1 3589/4885KMT2A 1948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.